Figure 2.

BCMAlow multiple myeloma cells are sensitive to MCL-1 inhibition. (A) Mean fluorescence intensity (MFI) of B-cell maturation antigen (BCMA) (expressed as x-fold of MFI in untreated controls) as measured by flow cytometry in alive multiple myeloma (MM) cells after treatment with either 4 nM Bortezomib (Bor), 1,000 nM dexamethasone (Dex), 100 nM BCL-2 inhibitor (BCL-2i; ABT-199), or 100 nM MCL-1i (S63845) for 24 hours (n=4-9). Each dot represents an individual sample. Statistical differences between groups were analyzed using a one-way ANOVA with Bonferronis’ multiple comparison test. **P<0.01. (B) Representative histograms showing BCMA expression in MM cells from 4 different primary samples (MM1-MM4) cultured in Puramatrix (PMX). Histograms show BCMA in alive MM cells untreated (black) or after a 24-hour treatment with 100 nM MCL-1i (red).